1 / 6

Companion Diagnostics Market estimated worth $8,730.7 Million by 2019

The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3136.9 million in 2014, at a CAGR of 22.7% during the forecast period (2014 to 2019).

dhruv13
Download Presentation

Companion Diagnostics Market estimated worth $8,730.7 Million by 2019

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MarketsandMarkets Presents Companion Diagnostics Market – North America to Offer Significant Growth Opportunities http://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html

  2. The "Companion Diagnostics Market by Technology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer) & End-user (Pharmaceutical Companies, Reference Lab)- Global Trends & Forecasts to 2019". The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3136.9 million in 2014, at a CAGR of 22.7% during the forecast period (2014 to 2019). Browse: 57 market data tables 36figures 142pages and in-depth TOC on "Companion Diagnostics Market” Download The PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=155571681 The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7%. http://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html

  3. The growth of this market can be attributed to the growing demand of targeted drugs in oncology, neurology, and infectious diseases and the support from regulatory authorities across the globe. Ask For Discount@ http://www.marketsandmarkets.com/discountreports.asp?id=155571681 Advanced technologies such as next-generation sequencing (NGS), increasing adoption of companion diagnostic kits/tests by the pharmaceutical industry, and encouragement from regulatory bodies are expected to boost the global market. Increasing costs of drug discovery; continuous focus on customized medicines for cancer; infectious, cardiovascular, neurological, and autoimmune diseases; and the need for technically advanced diagnostics has stimulated pharmaceutical firms to enter into the market. In 2013, many new molecular entities (NMEs) were approved by a pharmacogenomics biomarker from the FDA. . http://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html

  4. To capture this market, pharmaceutical firms are striving to enter into the global market through strategic acquisitions and collaborations with NGS platform diagnostic firms. Moreover, the end results of NGS is superior as compared to other technologies, as NGS provides a wider definition of genome sequencing that will fuel the adoption of NGS-based companion diagnostic in the future. This study also illustrates the major market players who have made a remarkable contribution in the global market. The major players of this market are Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), and QIAGEN N.V. (Netherlands). http://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html

  5. About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pinpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.  http://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html

  6. Contact Us Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441 Email: sales@marketsandmarkets.comMarketsandMarkets Bloghttp://www.marketsandmarkets.comhttp://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets

More Related